- Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
- Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
- Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
- Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
- Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
- Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025
- Axogen Announces Promotions on Research and Development Team
- Axogen, Inc. Appoints Kathy Weiler to its Board of Directors
- Axogen Announces Transition of Finance Team Leadership
More ▼
Key statistics
As of last trade, AxoGen Inc (AXGN:NAQ) traded at 6.44, 86.67% above the 52 week low of 3.45 set on Nov 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.45 |
---|---|
High | 6.60 |
Low | 6.40 |
Bid | 6.43 |
Offer | 6.45 |
Previous close | 6.55 |
Average volume | 269.09k |
---|---|
Shares outstanding | 43.21m |
Free float | 40.21m |
P/E (TTM) | -- |
Market cap | 283.00m USD |
EPS (TTM) | -0.5070 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 17:51 BST.
More ▼